Biocon rises after EU approves pertuzumab biosimilar for breast cancer treatment
Mumbai, Nov. 18 -- The approval makes Biocon's pertuzumab the first biosimilar to receive European Commission marketing authorisation under the European Medicines Agency's (EMA) new tailored clinical approach. It follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on 17 September 2026.
The biosimilar is approved as a 420 mg concentrate for solution for infusion. It is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant and adjuvant treatment of eligible adult patients with HER2-positive breast cancer. It is also approved for treating HER2-positive metastatic or locally recurrent unresectable breast cancer in combination with trastuzumab and docetaxel.
Biocon said th...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.